Note 5 - Supplemental disclosure for statement of cash flows

In the years ended July 31, 2023 and 2022, interest paid by the Company, including penalties and fees approximated $1,246 and $231, respectively.

For the years ended July 31, 2023 and 2022, the net reductions in the measurement of right of use assets and liabilities included in cash flows from operating activities was approximately $38 and $29, respectively. The changes are included in changes in accrued liabilities, other current liabilities, and other liabilities in the statements of cash flows.

In connection with the completed sale of certain assets used in the operation of Enzo Clinical Labs, $5,000 of proceeds were included in other assets as escrow as of July 31, 2023.

For the years ended July 31, 2023 and 2022, tax on capital paid by the Company was $22 and $129 respectively. There was no cash paid for income taxes by the Company for the years ended July 31, 2023 and 2022.

During the years ended July 31, 2023 and 2022, the Company issued common stock in connection with its share-based 401(k) employer match in the amount of $1,079 and $814, respectively.